RAS, KIT, FLT3 and JAK2 gene mutations in Acute Myeloid Leukemia (AML) with inv(16) and t(8;21) [Elektronische Ressource] : incidence and relevance on clinical outcome / presented by Juan Du

UniversitätsklinikumUlmZentrumfürInnereMedizinKlinikfürInnereMedizinIIIHämatologie,Onkologie,RheumatologieundInfektionskrankheitenÄrztlicherDirektor:Prof.Dr.med.HartmutDöhner RAS,KIT,FLT3andJAK2 GeneMutationsinAcuteMyeloidLeukemia(AML)withinv(16)andt(8;21):IncidenceandRelevanceonClinicalOutcomeDissertation fortheattainmentoftheDoctoralDegreeofMedicine(Dr.med.)attheFacultyofMedicine,UniversityofUlm,Ulm,GermanyPresentedbyJuanDuborninMudanjiang,HeilongjiangProvince,P.R.China2007 AmtierenderDekan:1.Berichterstatter:2.Berichterstatter:TagderPromotion: ContentContent Abbreviations………………………………………………………………III 1. Introduction........................................................................................... 1 1.1. Acutemyeloidleukemia.......................................................................... 1 1.2. Prognosticsubgroupsbasedoncytogeneticfindings............................. 3 1.2.1. Corebindingfactor(CBF)acutemyeloidleukemia................................. 5 1.3. MutationclassesinAML......................................................................... 9 1.3.1. ClassImutations .................................................................................. 10 1.3.2. ClassIImutations ..............................................................